- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02017418
The Effects of a Zeaxanthin Intervention on Visuomotor Function
May 26, 2015 updated by: Billy R. Hammond, University of Georgia
This study was designed to test whether two zeaxanthin formulations (supplements containing different nutritional compounds with zeaxanthin and omega fatty acids being the primary ingredients of interest) influenced visual motor function.
Visual motor function refers to the processing speed of the visual system and how individuals respond behavioral to visual stimuli (e.g., reaction time).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study was designed to test whether two zeaxanthin formulations (supplements containing different nutritional compounds with zeaxanthin and omega fatty acids being the primary ingredients of interest) influenced visual motor function.
Visual motor function refers to the processing speed of the visual system and how individuals respond behavioral to visual stimuli (e.g., reaction time).
Study Type
Interventional
Enrollment (Actual)
102
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Athens, Georgia, United States, 30602
- Department of Psychology, UGA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: ≥18 and ≤ 40 years
- BMI: ≥ 20 and ≤ 30 kg/m2
- No anticipated changes in dieting habits (as relevant to the intake of xanthophylls and fats/oils).
- No anticipated surgical procedures.
- Willingness and ability to give written informed consent and willingness and ability to comply with the study requirements.
- Corrected visual acuity (ETDRS): better than 20/60 in the eye selected for the study
Exclusion Criteria:
- Smokers
- Current or history of relevant ocular diseases (such as AMD) or other conditions e.g., lipid disorders.
- Inability to reliably perform macular pigment optical density measurements by "Heterochromatic Flicker Photometry" or any of the other ophthalmic tests of the study.
- Any condition likely to interfere with normal gastro-intestinal absorption of xanthophylls (e.g., digestive disorders: inflammatory bowel disease, ulcerative colitis, Crohn's, irritable bowel, etc. or lipid disorders including conditions such as hypercholesterolemia)
- Current use of xanthophyll containing supplements or use of xanthophyll containing supplements in the past 6 months (but excluding multivitamins containing lutein or zeaxanthin at low potency).
- Participation in any other study during last 1 month before study initiation.
- Known hypersensitivity or allergy to xanthophylls.
- Regular intake of medications or supplements, which the principal investigator deems likely to confound the study outcomes. These include diabetes medication and statins or any other drug/supplement to modulate cholesterol or fat digestion/absorption.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: zeaxanthin
placebo zeaxanthin
|
softgel
|
|
ACTIVE_COMPARATOR: combinatory supplement
placebo combinatory supplement
|
softgel
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Macular pigment optical density
Time Frame: one year
|
Increases in the amount of macular pigment measured in optical density units
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
fixed reaction time
Time Frame: one year
|
reaction time to a stimulus fixed in space
|
one year
|
|
variable reaction time
Time Frame: 12-months
|
reaction time to a stimulus with a position that varies in space
|
12-months
|
|
coincidence anticipation
Time Frame: 12-months
|
button press when a light stimulus of varying speeds reaches a specific point in a linear light array
|
12-months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Billy R Hammond, Ph.D., University of Georgia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (ACTUAL)
July 1, 2014
Study Completion (ACTUAL)
July 1, 2014
Study Registration Dates
First Submitted
December 16, 2013
First Submitted That Met QC Criteria
December 16, 2013
First Posted (ESTIMATE)
December 20, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
May 27, 2015
Last Update Submitted That Met QC Criteria
May 26, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Other Study ID Numbers
- 2012-10531
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Behavior and Behavior Mechanisms
-
University of FloridaNational Institute of Dental and Craniofacial Research (NIDCR)RecruitingChild Behavior | Behavior and Behavior MechanismsUnited States
-
Christian RuffNot yet recruitingBehavior and Behavior Mechanisms
-
Duke UniversityTerminatedBehavior and Behavior MechanismsUnited States
-
New York UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Hôpital le VinatierTerminatedBehavior and Behavior MechanismsFrance
-
New York UniversityPlanned Parenthood Federation of AmericaCompletedBehavior and Behavior MechanismsUnited States
-
New York UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedBehavior and Behavior MechanismsUnited States
-
Johns Hopkins UniversityCompletedBehavior and Behavior MechanismsUnited States
-
University of MichiganRobert Wood Johnson FoundationCompletedBehavior and Behavior MechanismsUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH)CompletedBehavior and Behavior MechanismsUnited States
Clinical Trials on zeaxanthin
-
Peking UniversityCompletedAge-related Macular DegenerationChina
-
Chrysantis, Inc.Kowa Company, Ltd.; IMAGE TECHNOLOGIES INC.CompletedCognition Disorders | Age Related Macular DegenerationUnited States
-
Valley Health SystemRecruitingMetastatic Solid Tumor | Cancer MetastaticUnited States
-
Paul S. BernsteinCompletedIdiopathic Juxtafoveal TelangiectasiaUnited States
-
Federal University of São PauloCompletedProliferative Diabetic Retinopathy | Epiretinal Membrane | Macular HoleBrazil
-
University of GeorgiaDSM Nutritional Products, Inc.Completed
-
Centre for Eye Research IrelandCompleted
-
National Eye Institute (NEI)National Heart, Lung, and Blood Institute (NHLBI); National Center for Complementary... and other collaboratorsCompletedAge-related Macular Degeneration | CataractUnited States
-
Johns Hopkins UniversityClark Charitable Foundation Inc.CompletedOcular Albinism (OA) | Oculocutaneous Albinism (OCA)United States
-
University Hospital, BordeauxVilmorin & CieTerminatedAge Macular DegenerationFrance